Abstract Search

ea0099p225 | Adrenal and Cardiovascular Endocrinology | ECE2024

Baseline characteristics of children and adolescents with classic congenital adrenal hyperplasia enrolled in CAHtalyst pediatric, a phase 3 Study of Crinecerfont, a corticotropin-releasing factor type 1 receptor antagonist

Sarafoglou Kyriakie , Kim Mimi , Lodish Maya , Felner Eric , Martinerie Laetitia , Nokoff Natalie J. , Clemente Maria , Fechner Patricia Y. , Vogiatzi Maria , Speiser Phyllis , Sturgeon Julia , Roberts Eiry , Jeha George , Chan Jean L. , Farber Robert

Objective: To describe the baseline characteristics of individuals enrolled in CAHtalyst Pediatric (NCT04806451), a randomized, double-blind, placebo-controlled, Phase 3 study evaluating the safety and efficacy of crinecerfont (a corticotropin-releasing factor type 1 receptor [CRF1] antagonist) in children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21-OHD CAH).Methods: Key eligibility criteria...

2 shares

Endocrine Abstracts

Baseline characteristics of children and adolescents with classic congenital adrenal hyperplasia enrolled in CAHtalyst pediatric, a phase 3 Study of Crinecerfont, a corticotropin-releasing factor type 1 receptor antagonist

BiosciAbstracts